← Leaderboards
Weizhou Zhang
University Of Florida
$6,977,638
Attributed
$9,528,497
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,528,497 · 7
By mechanism
R01$8,704,547 · 5
R00$713,790 · 1
K99$110,160 · 1
Top collaborators
- Guangrong Zheng7 shared
- Daohong Zhou5 shared
- Keiran Smalley2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsWomanNeoplasm MetastasisSpecimenMalignant Breast NeoplasmCellsTumorGeneticSignal TransductionPreventTumor GrowthImmuneT-LymphocyteMediatingLeadPathway InteractionsCessation Of LifeTumor ProgressionBreast Cancer PatientRegulatory T-LymphocyteCancer TypeExhibitsBreast Cancer ModelCancer Cell
Grant awards (25)
Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy$655,441
R01 · FY2025 · CA · contact PI
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$514,305
R01 · FY2025 · CA · contact PI
Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas$499,609
R01 · FY2025 · CA · contact PI
Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy$678,605
R01 · FY2024 · CA · contact PI
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$486,504
R01 · FY2024 · CA · contact PI
Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas$424,015
R01 · FY2024 · CA · contact PI
Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas$505,159
R01 · FY2023 · CA · contact PI
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$497,648
R01 · FY2023 · CA · contact PI
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$493,605
R01 · FY2022 · CA · contact PI
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$500,180
R01 · FY2021 · CA · contact PI
Obesity, inflammation and breast cancer$348,842
R01 · FY2020 · CA · contact PI
CD177 suppresses breast-cancer development by inhibiting beta-catenin$342,002
R01 · FY2020 · CA · contact PI
Obesity, inflammation and breast cancer$338,379
R01 · FY2019 · CA · contact PI
CD177 suppresses breast-cancer development by inhibiting beta-catenin$332,344
R01 · FY2019 · CA · contact PI
Obesity, inflammation and breast cancer$347,787
R01 · FY2018 · CA · contact PI
CD177 suppresses breast-cancer development by inhibiting beta-catenin$204,161
R01 · FY2018 · CA · contact PI
CD177 suppresses breast-cancer development by inhibiting beta-catenin$144,683
R01 · FY2018 · CA · contact PI
CD177 suppresses breast-cancer development by inhibiting beta-catenin$348,844
R01 · FY2017 · CA · contact PI
Obesity, inflammation and breast cancer$347,787
R01 · FY2017 · CA · contact PI
CD177 suppresses breast-cancer development by inhibiting beta-catenin$348,844
R01 · FY2016 · CA · contact PI
Obesity, inflammation and breast cancer$345,803
R01 · FY2016 · CA · contact PI
Myofibroblasts, T cells and malignant cells interplay in breast cancer metastasis$234,222
R00 · FY2014 · CA · contact PI
Myofibroblasts, T cells and malignant cells interplay in breast cancer metastasis$230,569
R00 · FY2013 · CA · contact PI
Myofibroblasts, T cells and malignant cells interplay in breast cancer metastasis$248,999
R00 · FY2012 · CA · contact PI
Myofibroblasts, T cells and malignant cells interplay in breast cancer metastasis$110,160
K99 · FY2011 · CA · contact PI